Over the last two decades, there have been tremendous advances in the non-invasive
diagnosis and risk stratification of chronic liver diseases (CLDs). Non-invasive approaches …

Nonalcoholic fatty liver disease (NAFLD) is estimated to afflict approximately 1 billion
individuals worldwide. In a subset of NAFLD patients, who have the progressive form of …

Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic
fatty liver disease. The aims of this study were to evaluate the individual diagnostic …

Background & Aims Large prospective studies to establish the prevalence of non-alcoholic
fatty liver disease (NAFLD) and steatohepatitis (NASH), are lacking. We prospectively …

Background & Aims We estimated the accuracy of FibroScan vibration-controlled transient
elastography controlled attenuation parameter (CAP) and liver stiffness measurement …

Background & Aims Recently, a group of hepatologists proposed to rename non-alcoholic
fatty liver disease (NAFLD) as metabolic associated fatty liver disease (MAFLD) with …

Background Diagnostic tools for liver disease can now include estimation of the grade of
hepatic steatosis (S0 to S3). Controlled attenuation parameter (CAP) is a non-invasive …

We present here the first update of the 2013 EFSUMB (European Federation of Societies for
Ultrasound in Medicine and Biology) Guidelines and Recommendations on the clinical use …

Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver
disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is …

Background & Aims The prevalence of fatty liver underscores the need for non-invasive
characterization of steatosis, such as the ultrasound based controlled attenuation parameter …